| NCT ID | NCT05824364 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Don Carlo Gnocchi Onlus |
| Condition | Heart Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-05-20 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-05-20 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Registry-based randomized clinical trial (RRCT) to assess the safety and efficacy of two different schemes of exercise training in patients who have recently undergone heart transplantation
Eligibility Criteria
Inclusion Criteria: * All the patients admitted in the on-site CR after HTx Exclusion Criteria: * unable to sign informed consent
Contact & Investigator
Nuccia Morici, MD
PRINCIPAL INVESTIGATOR
IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
Frequently Asked Questions
Who can join the NCT05824364 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05824364 currently recruiting?
Yes, NCT05824364 is actively recruiting participants. Contact the research team at nmorici@dongnocchi.it for enrollment information.
Where is the NCT05824364 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05824364 clinical trial?
NCT05824364 is sponsored by Fondazione Don Carlo Gnocchi Onlus. The principal investigator is Nuccia Morici, MD at IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy. The trial plans to enroll 40 participants.